2023

  1. Vedolizumab, adalimumab and methotrexate combination in CD

  2. Vedolizumab in children with IBD

  3. Phase 2 trial, guselkumab in Crohn’s disease efficacy and safety at week 48

  4. Adalimumab increased interval in CD

  5. LAG-3 depleting antibody GSK2831781 in UC

  6. Mirikizumab induction and maintenance

  7. Mercaptopurine in UC for maintenance

  8. Mediterranean Diet vs Canadian diet in quiescent UC

  9. Olamkicept induction in ulcerative colitis

  10. Over-the-Counter Multivitamin and Mineral Supplement to Prevent Infections in IBD Patients